Stifel resumed coverage of Syndax (SNDX) with a Buy rating and $44 price target The firm believes the commercial launches of two of the company’s assets create a path to non-GAAP profitability in the second half of fiscal 2026. Each asset has $1B-plus in peak sales potential and are still in the very early stages of growth, the analyst tells investors in a research note. Stifel views Syndax’s valuation as compelling at current levels.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNDX:
- Optimistic Buy Rating for Syndax Pharmaceuticals Driven by Promising Market Position and Growth Potential
- Syndax assumed with a Buy at Guggenheim
- Syndax Pharmaceuticals’ Axatilimab Study: A Potential Breakthrough for IPF Treatment
- 3 Best Stocks to Buy Now, 8/6/2025, According to Top Analysts
- Syndax Pharmaceuticals Faces Ongoing and Emerging Business Risks: A Closer Look at SEC Filings